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Abstract 
This paper summarizes the recent activities of the Chromosome-Centric Human Proteome Project (C-
HPP) consortium, which develops new technologies to identify yet-to-be annotated proteins (termed 
“missing proteins”) in biological samples that lack sufficient experimental evidence at the protein level 
for confident protein identification. The C-HPP also aims to identify new protein forms that may be 
caused by genetic variability, post-translational modifications, and alternative splicing. Proteogenomic 
data integration forms the basis of the C-HPP’s activities; therefore, we have summarized some of key 
approaches and their roles in the project. We present new analytical technologies that improve the 
chemical space and lower detection limits coupled with bioinformatics tools and some publicly 
available resources that can be used to improve data analysis or support the development of analytical 
assays. Most of this paper’s contents have been compiled from posters, slides, and discussions 
presented in the series of C-HPP workshops held during 2014. All data (posters, presentations) used are 
available at the C-HPP Wiki (http://c-hpp.webhosting.rug.nl/) and in the supporting information. 
 
Introduction 
Proteins such as those acting as enzymes, regulatory proteins, transporters, and receptors are the active 
macromolecules of human biology and are thus central to understanding biological molecular 
processes. Understanding the diversity and complexity of these biological molecular interactions is a 
central focus of bio-medical research today. It is important that all protein forms of human genes are 
eventually studied so that their biological functions and roles in healthy and disease states can be 
determined [posters 17 and 18 in Table 1]
1-3
. Proteins cannot be amplified and are chemically much 
more heterogeneous than DNA and RNA. Their analysis therefore represents a much more significant 
analytical challenge. 
9 
To meet this challenge, the Human Proteome Organization (HUPO) announced in 2010 at the HUPO 
Congress in Sydney, Australia, the formation of the Human Proteome Project (HPP) to sequentially 
catalogue the protein products of human genes, both to identify proteins that have little or no evidence 
at the protein level, termed “missing proteins”4, 5, and to discover and characterize protein sequence 
variability with genetic origin and post-translational modifications (PTM) of known proteins. The 
Chromosome-Centric Human Proteome Project (C-HPP)
4-6
 is a large multidisciplinary international 
effort to identify all human protein forms and catalogue them on the basis of the chromosome location 
of their coding genes. In the C-HPP, one national or multinational team is responsible for the 
identification and annotation of protein products of the genes in each chromosome. Evidence at the 
protein level means that a protein has been detected, preferably by mass spectrometry (MS) and 
preferably from multiple peptides unique to the protein observed in multiple experiments and possibly 
in diverse biological sample types. Multiple data resources help to provide information on protein 
evidence. 
The sharing of data, protocols, and other electronic resources such as proteome annotations is crucial in 
the C-HPP and proteomics community to enable the reuse of collected information (e.g., in form of 
high-quality spectral libraries for spectral library identification or the development of selected reaction 
monitoring [SRM] assays) and to develop and improve new data analysis protocols. The current status 
and developments in the shared proteomics data and proteome knowledge by the main stakeholders are 
presented below. An overview of current bioinformatics resources and the data flow to support the 
creation of complete part lists of the human proteome is shown in Figure 1. 
The ProteomeXchange
7
 consortium, led by PRIDE
8, 9
 at the European Bioinformatics Institute 
(Hinxton/Cambridge, UK) and by PeptideAtlas
10-12
 at the Institute for Systems Biology (Seattle, 
Washington, USA), is devoted to the standardization of data submission and dissemination of MS-
based proteomics data and to the promotion of public sharing of proteomics data in the public domain. 
10 
In addition, it promotes the use of community data standards developed by the Proteomics Standards 
Initiative (PSI). As such, ProteomeXchange resources store original MS datasets, containing at least the 
raw MS data accompanied by the processed results (peptide and protein identifications, but possibly 
quantitative information as well) and by suitable experimental and technical metadata. By November 
2014, ProteomeXchange resources stored approximately 1500 datasets (~50% of which are publicly 
available) from a wide variety of sources, with humans being the most-represented species. Once the 
datasets are made publicly available, they are usually reprocessed by PeptideAtlas
10-12
 using the Trans 
Proteomic Pipeline (TPP)
13-17
 and by the Global Proteome Machine Database (gpmDB)
18, 19
 using the 
X!Tandem
20, 21
 database search tool. Basically, everyone in the community can reanalyze the raw data 
available in ProteomeXchange for different purposes. 
To provide a comprehensive view of the human proteome and its diversity, neXtProt
22, 23
 is adding 
information at the genomic, transcriptomic and proteomic levels to the corpus of information available 
in UniProtKB
24-26
. In particular, neXtProt integrates genomic variation data from dbSNP
27
 and 
COSMIC
28
, transcriptomic data from BGee
29
, antibody-based protein evidence from the Human 
Protein Atlas (HPA)
30, 31
, MS-based information from PeptideAtlas
10-12
, three-dimensional structural 
information from the Protein Data Bank
32
 and various PTM information from manually curated 
literature. Based on this combined information, neXtProt attributes a protein existence (PE) level to 
each entry originally defined in UniProtKB. The PE1 level (experimental evidence at the protein level) 
denotes entries with credible evidence by protein expression and identiﬁcation by MS, 
immunohistochemical analysis, three-dimensional structure, or amino acid sequencing. The PE2 level 
(experimental evidence at transcript level) refers to proteins with transcript expression evidence but 
without evidence of protein detection. The PE3 level (protein inferred from homology) is attributed to 
proteins without human protein or transcript evidence but with strong evidence on homologous protein 
in another species. The PE4 level (protein predicted) is for proteins that are hypothesized from gene 
11 
models, and the PE5 level (protein and gene uncertain) refers to “dubious” or “uncertain” genes that at 
one time seemed to have some protein-level evidence but have since been deemed doubtful. The PE5 
category generally corresponds to pseudogenes or non-coding RNAs according to the protein 
annotation from different resources (HGNC
33
, RefSeq
34, 35
, HAVANA, CCDS
36-38
, UniProtKB/Swiss-
Prot
39
). Among the 643 entries in the PE5 category in neXtProt in August 2011, 119 have already 
become obsolete in UniProtKB and have been deleted from neXtProt, 13 have been upgraded to the 
PE1 category due to manual curation of publications and/or convincing proteomics data, and 11 have 
been upgraded to the PE2 or PE3 categories. Based on these numbers, one can estimate that less than 
5% (< 30) of the remaining PE5 proteins in neXtProt are true proteins. Given this low probability, any 
MS identification of PE5 proteins must be carefully checked. Proteins in the PE2-4 categories are 
awaiting experimental confirmation at the protein level and are called “missing proteins” in the context 
of C-HPP. 
One of the primary tasks of the C-HPP is to determine why no protein products have been identified for 
certain genes showing open reading frame for translation, i.e., genes coding for the so-called “missing 
proteins with no or poor protein evidence.” There are five main reasons for the existence of “missing 
proteins” (Figure 2)40. (1) The current mainstream proteomics technology cannot identify them, 
possibly because of the low abundance of the proteins, because the sequences do not contain tryptic 
cleavage sites or generate peptides which can uniquely identify the proteins, or because the protein 
digestion results of peptides that are lost during the sample preparation and analysis. (2) They are 
expressed only in rarely studied tissues or cell types, or are expressed only as a result of a stimulus or 
perturbation. (3) They are not expressed at all and are part of the silent information of the human 
genome. (4) They reflect erroneous annotation of the genome, which results in incorrectly predicted 
protein sequences. (5) Many highly homologous proteins or proteins with large sequence variability are 
missed or not counted due to the parsimonious protein assembly of shotgun MS/MS protein 
12 
identification or due to large sequence variability such as immunoglobulins. PeptideAtlas and gpmDB 
select only one “representative protein” among highly homologous members of protein families40 when 
the available sequence coverage cannot distinguish these related proteins (see the Cedar scheme in 
Farrah et al.
41
 and Figure S1 in the supporting information). 
When the C-HPP began (2012), it was announced that no satisfactory evidence existed at the protein 
level for 6568 (33%) of the 20,059 protein-coding genes
42
. NeXtProt released a new version as of 
September 19, 2014, that contains 20,055 entries, among which 16,491 are PE1 proteins, 2948 lack 
protein evidence (PE2, PE3, PE4), and 616 are dubious (PE5). Hence, there is still insufficient evidence 
at the protein level for approximately 15% (if we exclude PE5) or 18% of the human proteome. It is 
encouraging to see that the number of missing proteins has been reduced considerably since the initial 
assessment by the C-HPP in 2012. 
This paper presents an overview of the new technologies and new resources that have been used during 
the last 4 years by members of the C-HPP consortium and others to identify missing proteins. Most of 
the contents described here have been obtained from data presented during several HUPO workshops in 
2014, including the 9
th
, 10
th
 and 11
th
 C-HPP Workshops in Busan, South-Korea (26 March), Bangkok, 
Thailand (9 August) and Segovia, Spain (9 October), respectively, and during the C-HPP and HPP 
sessions of the HUPO 2014 Congress in Madrid, Spain (5-8 October). 
Proteogenomics 
Analytical technologies and bioinformatics are the key components for the identification and 
quantification of proteins in a complex biological sample. The current workhorse of proteomics 
analysis is shotgun LC-MS/MS, typically using a C18 stationary phase and acetonitrile/water eluent 
pairs, resulting in sequence coverage typically lower than 30% for identified proteins. Additionally, 
most of the collected MS/MS spectra contain gaps in the fragment ion series, thus preventing de novo 
13 
peptide sequence spectra interpretation and identification
43
. The most widely used approach for protein 
identification is database searching, which requires a list of protein sequences that are expected to be 
present in the analyzed samples. UniProtKB is the most frequently used protein sequence database. It 
has two main components: UniProtKB/SwissProt (which contains manually curated sequences) and 
UniProtKB/TrEMBL
44
 (which contains computationally generated records from DNA sequences that 
have not been manually curated). Canonical sequences are used to represent the most prevalent 
sequences that are most similar to those of other species and in which the length or amino acid 
composition allows the clearest description of protein domains, splice isoforms, polymorphisms, and 
PTMs. UniProtKB contains some degree of protein isoform information and sequence variation due to 
genetic variability, but it is far from complete. This results in a low level of identification of peptides 
that arise from alternative splicing, coding non-synonymous single-nucleotide polymorphisms (SNPs), 
and single amino acid variants (SAVs) due to RNA editing
45, 46
. Therefore a proteogenomic approach 
using DNA and mRNA data to build a protein database that contains all genetic variability or sample-
specific protein sequence information is becoming more and more popular and has contributed to the 
identification of new protein forms
47
. Conversely, peptide-level data can serve to fill gaps or correct 
errors in the DNA and RNA databases
47, 48
. There are two main proteogenomic approaches: (1) a 
protein sequence database is constructed from publicly available databases that contain sequence 
information with genetic variability such as dbSNP
27, 49
 or H-INVDB
50
, or (2) a customized protein 
sequence database is constructed from annotated DNA and mRNA transcript data obtained from the 
same sample
51-53
. However, proteogenomic analysis generally results in a larger database than does 
using the UniProtKB canonical sequences, and should be followed through false discovery rate (FDR) 
analysis at both the peptide and protein levels
13, 47
, especially when the database search is performed in 
multiple steps
47, 54
. PeptideProphet
55
 from TPP and Percolator
56-58
 can be used for FDR calculations for 
peptide spectrum matches (PSMs). ProteinProphet
59
 and MAYU
17
 (both from TPP) serve to estimate 
14 
FDR for protein inference. PeptideShaker
60, 61
 provides a solution for both PSM and protein FDR 
calculation. The statistical power of PSM in separating correct and incorrect PSM distributions can be 
enhanced by including the measurable and predictable physico-chemical properties of peptides in 
addition to m/z, such as the retention time in liquid chromatography
62
 or the high-resolution isoelectric 
point
63
. Identification of missing proteins can be enhanced by identifying cell lines and tissue samples 
with transcriptomics evidence [poster 12], analyzing samples of different ages, and including samples 
acquired under special stress conditions and biological perturbations. 
A general drawback of bottom-up shotgun LC-MS/MS approaches is that complete protein forms 
cannot be reconstituted from peptide fragments. A top-down approach that allows the peptide-protein 
interference problem to be avoided may provide a solution for determination of the accurate 
distribution of whole protein forms, also called proteoforms
64
. Proteoforms are the most recent 
nomenclature of protein forms introduced by the Top Down Proteomics Consortium, which “designates 
all of the different molecular forms in which the protein product of a single gene can be found, 
including changes due to genetic variations, alternatively spliced RNA transcripts and post-translational 
modifications”. The relationship of the proteoform terminology to the UniProt canonical sequences and 
other protein sequence variability or modifications is shown in Figure S2 in the supporting 
information. Importantly, unlike bottom-up protocols in which detailed information on PTMs and 
sequence variants is compromised because of enzymatic digestion, intact proteins are analyzed in top-
down approaches, which allows the unequivocal identification and location of specific modifications. 
However, they require relatively pure protein samples, they are restricted to proteins of less than 30 
kDa, the available fragmentation spectra are often far from complete, and the obtained complex spectra 
are often difficult to interpret
64-67
. 
Analysis of mRNA has an advantage in that sequences can be amplified to provide nearly complete 
sequence coverage using current RNA sequencing technologies. The challenge is to accurately annotate 
15 
the resulting raw DNA and RNA data, which is generally performed using the Ensembl genome 
browser
68
. Ensembl contains a reference genome and includes annotation from the Encyclopedia of the 
DNA Elements (ENCODE)
69, 70
 which is a “comprehensive parts list of functional elements in the 
human genome, including elements that act at the protein and RNA levels, and regulatory elements that 
control cells and circumstances in which a gene is active.” However, protein-coding gene annotations 
such as GENCODE
71
 are based on the protein sequences stored in public databases such as UniProtKB 
or NCBI RefSeq
35
 and gene models that predict the long open reading frames (ORFs) that are most 
likely to code a protein, which can lead to errors in the annotation of these databases. Therefore, 
besides revealing protein forms due to genetic variability, a proteogenomic approach can help to 
confirm the existence of the 616 dubious human proteins currently annotated as PE5 in neXtProt. It can 
also support identification of new ORFs and translated non-coding mRNA, or redefine the starting and 
ending parts of protein coding regions, as reported by Kim et al
1, 72
. However when protein 
identification is performed exclusively with a translated mRNA sequence the much shorter half-life of 
mRNA compared to proteins
73, 74
 should be taken into account in the integration of proteogenomics 
data. The half-life difference between these two molecular species could result in proteins without 
mRNA when proteins and mRNA are measured in the same sample and at a single time point. Time 
series sampling could be used to overcome this issue, when it is possible. This is the case for cell 
cultures, blood or animal experiments, or tissues for which multiple samples are available from the 
same specimen at different time. For other cases, the use of a combined databases from translated 
mRNA sequences and the UniProt database is an option for the detection of proteins with a half-life 
much longer than that of mRNA. 
Translating mRNA, which is directly upstream of protein expression, thus serves as a useful resource 
for protein identification
53
. Wang et al.
75
 performed the first translated mRNA sequencing (RNC-seq) 
in human lung cancer cell lines and observed an improved correlation of RNC-mRNA abundance with 
16 
translated protein when the RNC-mRNA length was taken into consideration. The same group showed 
that the genes with translation evidence represent an improved reference for the identification of 
proteins, the detection of sequence variations (SAV, RNA editing and alternative splicing), and 
integration of the MS data
53
. 
Furthermore, missing proteins with mRNA evidence and more stringent conditions with ribosome-
bound mRNA (RNC-mRNA) evidence are most probably translated, but the current proteomics 
technology does not allow their detection because of a restricted chemical space or because the 
detection sensitivity is not sufficient. According to the presentation from Zhang et al. (submitted 
manuscript) at the C-HPP workshop during the HUPO 2014 Congress in Madrid, ~5% of transcribed 
mRNAs are typically not translated in a single cell line, and these non-translated mRNAs are highly 
cell-type specific and/or tissue specific. This allows the focus to be placed on missing proteins in 
samples with translation evidence and the development of targeted SRM assays and specific sample 
preparation methods, e.g., the use of antibody enrichment of missing proteins for low abundant 
peptides or the use of different proteases when missing proteins do not contain identifiable unique 
tryptic peptides with the detected tryptic peptide set. 
An example of a proteogenomic study in which translated mRNA analysis, proteomics data integration, 
and the use of antibodies were performed to enrich low abundant proteins was presented by Chang et 
al.
52
 from the Chinese Human Chromosome Proteome Consortium covering chromosomes 1, 8, and 20. 
In their study, three hepatocellular carcinoma cell lines (Hep3B, HCCLM3, and MHCC97H) were 
submitted for mRNA and RNC-mRNA analysis and to comprehensive analysis with deep proteomics 
and antibody-enriched transcription factor proteomics. Based on the integrated data, they concluded 
that only 50.2% of the protein-coding genes with translation evidence were found in the proteomic 
data. This result is comparable to that of a previous study on the RNC-mRNA and MS data of Caco-2 
cells: 52.6% of the proteins with translation evidence were missing from the LC-MS/MS data acquired 
17 
from institutions
53
. The inability to detect certain proteins by LC-MS/MS was most probably a results 
of the translation control mechanisms and analytical limitations of MS-based shotgun identification of 
peptides and proteins. This warrants a survey of missing proteins in other resources and strategies, such 
as detergent-insoluble fractions of cell/tissue lysates and forced gene expression through epigenetic 
manipulations. 
Integrating alternatively spliced transcripts with proteomics information allows the study of the 
transcriptional regulation of proteins in both healthy and diseased tissue [poster 8 and 13]. This effect 
was shown by Menon et al.
76
, who integrated RNA-seq and proteomics data as part of the chromosome 
17 team and identified more than one splice variant for each of 1167 genes expressed in at least one of 
three breast cancer cell line models ERBB2+SKBR3, ERBB2+ SUM190, and 
EGFR(ERBB1)+SUM149, of hormone receptor–negative breast cancers. Their data analysis showed 
high differences between alternative splicing distributions in the three different cell lines, which were 
distinctively enriched for different key cell functions such as amino acid and sugar metabolism, caspase 
activity, and endocytosis in SKBR3; aspects of metabolism, especially of lipids in SUM190; and cell 
adhesion, integrin and ERK1/ERK2 signaling, and translational control in SUM149. In poster 20, 
Menon and Omenn presented findings of recurrent non–canonical splice variants of interesting proteins 
in 126 triple-negative breast cancer specimens using data available from EBI/PRIDE. 
Another dimension of the proteogenomic splice isoform studies was presented in poster 21 by Li et al, 
who undertook genome-wide isoform-level protein connectivity analysis. The isoform with the highest 
connectivity seems to be more highly associated with function than the choice of a canonical protein 
isoform based on the sequence length or the abundance of the isoform, which are the methods 
commonly used in established databases. The genome-wide isoform analysis in mice has been 
reported
77
 and is under development for humans by the Chromosome 17 team (Li et al., unpublished). 
18 
Glioma stem cells (GSCs) isolated from patient tumors possess both stem-like and oncogenic patterns 
of protein expression and are thus a potential source of missing proteins. The Chromosome 19 team has 
characterized their expression profiles at both the transcript and protein levels. They analyzed 1382 
chromosome 19 genes in GSCs using a transcription microarray and showed that 70-75% of them were 
expressed in each of the studied cell lines
78
. The customized analyses identified differential gene 
expression patterns specific to chromosome 19 between subtypes of GSCs. It was found that roughly 
20% of the transcripts were differentially expressed in the proneural and classical subtypes in 
comparison to transcription patterns in human neuronal stem cells
79
. The chromosome 19 transcripts 
that potentially encoded candidate unidentified ORFs proteins were also investigated; 43 ORFs were 
represented on the arrays, of which 31 (72%) were expressed in the GSC lines. GSCs are also a source 
of protein variants. Recently, proteomic searches of high-resolution LC-MS/MS data of GSC protein 
digests identified 19 SAVs in 17 chromosome 19 proteins
1, 2
. Several of the protein variants may have 
oncogenic potential and are the subjects of further investigation. Furthermore, the integration of RNA-
seq and proteomic data made possible the study of the somatic-proteomic landscape of GSCs, thereby 
allowing the contribution of new knowledge regarding novel fusion proteins in GSC pathobiology. To 
summarize the current status of chromosome 19, Figure 3 shows the numbers of genes, mRNA, and 
proteins, including the number of “missing” proteins and the number of predicted molecular forms 
(such as mutant proteoforms) and known PTMs. This study and the preceding studies from the 
Chromosome 17 team illustrate the potential of involving new protein forms that arise from genetic 
variability and alternative splicing into the investigation of new biology. 
Enlarging the analyzed chemical space 
Proteins are composed of 20 amino acids and are known to be modified by more than 300 types of 
PTMs
80-82
, embracing a wide chemical space that should be covered by the proteomics analytical 
approach. In addition, artificial modifications introduced by the sampling protocol need to be 
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considered. This large chemical space is well covered, but not completely covered, by the widely used 
acetonitrile/water C18 LC-MS/MS protocols. For example, studies in multiple tissues and cells lines 
performed by the Chinese Human Chromosome Proteome Consortium
52
 showed that hydrophobicity 
(28%) and a low molecular mass (<30 kDa; 75%) are important physicochemical properties that predict 
unsuccessful detection of a protein. In contrast, the isoelectric point and half-life do not seem to play 
important roles in detectability. Unidentified proteins in hepatocellular carcinoma cell lines were 
enriched in specific cellular processes such as olfaction with non-liver function or mainly localize in 
the cell membrane, supporting the hydrophobicity-negative bias of the currently dominant method of 
proteomics analysis. Tissue transcript analysis showed that transcripts for the missing proteins are 
abundant in the testis. Interestingly, a recent analysis of data in the HPA has shown that more tissue-
specific proteins are made in the testis than in any other tissue in the body
83
. Analysis of the DNase I 
hypersensitivity of mRNA and RNC-mRNA data suggests that the missing proteins without a 
detectable signal are relatively enriched in the chromatin regions with low DNase I hypersensitivity 
( 40% of the missing proteins), which suggests that the specific structure of chromatin can repress the 
transcriptional process. Chromosome 11 (and to a lesser extent chromosome 19) showed a greater 
number of missing proteins without transcript evidence, and those missing proteins were densely 
clustered in several well-defined chromosome regions. One major group of these missing proteins is 
presumed to have olfaction function. 
Missing protein identification can be enhanced by developing specific enrichment methods such as the 
use of Proteominer beads
84, 85
 and enrichment of protein aggregates (Yang Chen, Yaxing Li, Jiayong 
Zhong, et al.; manuscript under review in JPR); specific analytical methods for hydrophobic proteins; a 
specific fractionation method such as the analysis of subcellular fractions [poster 5, 9 and 19]; and 
methods to increase protein sequence coverage (e.g., by using multiple proteases for protein cleavage
49
 
or by using a more efficient method of peptide fragmentation such as EThcD
86-88
). The membrane 
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subproteome was suggested to be a rich source of missing proteins. A deep sequencing strategy using 
complementary two-dimensional chromatography with a combination of high-pH reversed phase (RP), 
strong anion exchange and low-pH RP stationary phases was used to increase the measured dynamic 
concentration range. The preliminary results of the enriched membrane proteome from the group led by 
Yu-Ju Chen [poster 1] showed that high-pH RP columns enhanced the retention of hydrophobic 
peptides and increased the identification coverage of the missing membrane proteins (unpublished 
results). 
Lowering the detection limit with targeted SRM, SWATH analysis, ProteomeAnalyzer, and 
antibody enrichment 
SRM assays have been used for decades to quantify small compounds by MS. The laboratory of Ruedi 
Aebersold has further developed this approach into a standard method for proteomics to enable 
simultaneous multiplexed quantification of several hundred proteins in complex biological samples 
with a wide concentration dynamic range. Picotti et al.
89, 90
 showed the power of this method by 
detecting almost the complete proteome of yeast, covering 4.5 orders of magnitude of the dynamic 
concentration range. Large-scale application of SRM assays for targeted quantification of long human 
protein lists required not only the increased speed of the triple quadrupole instruments, but also the 
creation of such important informatics resources as high-quality spectral libraries (e.g., NIST spectral 
libraries, SRMAtlas
91
), repository of SRM assay results (PASSEL
92
), a database of ranked peptides and 
SRM transitions for all proteins in selected proteomes (SRMAtlas
91
), and a database of peptides and 
transitions with quantification calibration curves (SRMQuantAtlas). SRM assay development requires 
the identification of proteotypic peptides that not only map uniquely to a single protein or isoform but 
also are readily ionized and can be detected by MS with a high probability. The proteotypic sequence 
and SRM transitions must be unique to unequivocally identify the protein form among all other protein 
forms in the human proteome. This task, coupled with the processing and analysis of the acquired data, 
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is supported by step-specific algorithms and comprehensive bioinformatics pipelines
93
 to plan SRM 
assays for missing proteins, such as ATAQS
94
, mQuest
95
, MaRiMba
96
, SMRBuilder
97
, and Skyline
98
. 
The PeptidePicker tool developed by Mohammed Y et al.
99
 can help to select the most appropriate 
surrogate peptides for a given protein list in human and mouse proteomes to be used in targeted SRM 
assays based on the current knowledge of the community as presented in UniProtKB, PeptideAtlas, 
gpmDB, PRIDE and dbSNP. The tool identified has already reported peptides in online databases for 
missing proteins, although the quality of the data in these databases varies considerably. 
The data-independent sequential window acquisition workflow (SWATH-MS) allows collection of 
non-targeted fragment spectra by fragmenting large windows of precursor ions (typically 20 to 25 
Dam/z). The resulting MS/MS data can be reconstituted from the co-eluted fragment ions with liquid 
chromatography retention time using deconvolution methods. The SWATH approach also can be seen 
as a generalization of the SRM approach, in which each detectable fragment ion is measured and can be 
reconstituted from the acquired data without being restricted to a targeted list of transitions as in SRM. 
Recently, SWATHAtlas was introduced, which stores a human library of MS/MS spectra acquired on a 
TripleTOF instrument for 10,000 human proteins
100
. This library was obtained from 331 measurements 
on cell lines, blood, and other human tissues and is intended to be used by PeakView, the 
OpenSWATH tool
101
, and other analogous processing software, providing 51% of coverage of 
canonical UniProtKB/Swiss-Prot
39
 entries. 
Another important resource for the identification of missing proteins is SRMAtlas
91
, which contains a 
high-confidence “gold standard” quality SRM assay for at least one unique peptide for 99.9% of the 
canonical UniProtKB/Swiss-Prot
39
 entries. This high coverage was achieved by including MS/MS 
spectra obtained from a large campaign of production and analysis of synthetic peptides for the 
complete human proteome. Another source of MS/MS spectra and spectral libraries for phosphorylated 
and unmodified synthetic peptides is available for assay development
102
. 
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The development and application of SRM assays to complex biological samples is a well-established 
technology for protein quantification that requires expensive instrumentation and experienced 
personnel, which limits its utility in replacement of the commonly used western blot analysis for 
quantification of proteins. Following a planning period led by the HUPO Industrial Advisory Board 
and a survey of 266 participants, mostly from biology and clinically oriented laboratories, HUPO 
launched the ProteomeAnalyzer initiative in collaboration with instrument vendors with the goal of 
developing affordable SRM instrumentation capable of quantifying of 100 to 2000 proteins. 
Antibodies are effective reagents for the specific detection and enrichment of missing proteins
103
. The 
availability of highly specific and validated antibodies is crucial for the detection of low abundant 
missing proteins and the spatial characterization of their expression pattern in cells and tissues. The 
implementation of high-throughput production of validated high-affinity monoclonal antibodies using 
automated production systems will provide renewable resources
104, 105
. SISCAPA can enhance the 
sensitivity of SRM analyses by enriching specific peptides
106-108
. 
The HPA
31, 109
 project has systematically generated affinity purified polyclonal antibodies using 
proteospecific recombinant protein fragment and Protein Epitope Signature Tags (PrESTs)
110
. After a 
rigorous validation scheme, the approved antibodies are used to assess the spatial distributions of the 
proteins in a multitude of human cells and tissues by immunohistochemical analysis. The November 
2014 HPA release (version 13.0) contains more than 13 million images of protein expression patterns 
generated by the use of 23,968 validated antibodies targeting 16,943 genes. In addition to protein 
evidence, expression levels, and subcellular localization, the HPA contains mRNA expression levels 
for the majority of tissues and cell lines involved in the HPA
111
. The resources from HPA are highly 
valuable for the identification of cell lines and tissues that express missing proteins or for cross-
validation of MS or HPA antibody protein evidence. Methods for the use of PrEST antigens as spike-in 
reagents for quantitative MS were recently demonstrated
112
. Immuno-SILAC has proved capable of 
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absolute quantification of proteins in complex samples based on HPA antibodies and stable isotope-
labeled PrESTs to allow affinity enrichment before MS analysis and accurate quantification
113
. 
In a recent collaboration between the HPA group in Stockholm and the high throughput monoclonal 
antibody facility at Monash University in Melbourne a number of monoclonal antibodies against 
missing proteins, important signaling molecules and proteins of interest to the Chromosome 7 and 17 
groups were generated using the same PrESTs as immunogens, which will allow a direct comparison 
between monoclonal and polyclonal antibodies raised against the same prEST and generate new 
reagents for the proteomics community. Interestingly, in some cases it was possible to raise monoclonal 
antibodies to targets that had failed to generate polyclonals. This finding provides an additional route 
for completion of the task of generating renewable antibodies to all human proteins using the existing 
antigen resources. Lambert et al.
114
 recently showed that coupling affinity enrichment with quantitative 
MS techniques such as SWATH analysis provides the most sensitive detection method for low 
abundant missing proteins. 
Human sample resources 
Human samples are collected and stored in various locations worldwide and are crucial to the C-HPP 
project and to proteomics and disease research in general. Even if sensitive analytical methods are 
available to uniquely identify and detect missing proteins, high-quality human samples collected under 
strict standard operating procedures for collection, processing, and storage must be available to 
characterize protein expression. Although many countries have recognized this need and have 
established biobanks for the collection and storage of human samples available from local or regional 
resources, they have not always been collected under the optimal conditions required for the 
maintenance of the initial integrity of the protein constituent of samples for proteomics studies. Here, 
many factors leading to protein degradation need to be identified and addressed by the community. 
Therefore, as demonstrated by several groups
115-121
, sample collection and storage protocols should be 
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assessed and optimized in this respect for each sample type. For the C-HPP initiative, in addition to 
ensuring the sample quality, it is also important to exchange samples between laboratories in different 
countries, for which legal and ethical regulations should be in place. To facilitate the exchange of 
samples, HUPO will join forces with ISBER
122, 123
, an international organization that has worked out 
regulatory and ethical protocols and Best Practice guidelines
124
 for such purposes. 
Controlled vocabularies and ontologies pioneered by SNOMED
125
 providing standardised anatomical 
descriptors related to tissue types (BRENDA)
126, 127
, cell types (Cell Ontology)
128
, and human diseases 
(DOID, http://disease-ontology.org/)
129
 and common descriptions of clinical details, sampling, sample 
handling, and sample storage data are crucial to effectively compare and search metadata of the 
samples stored in biobanks and to enable studies that make use of samples from multiple biobanks. 
Biology and clinically related ontologies are accessible through the Ontology Lookup Service
130
 hosted 
at EBI (http://www.ebi.ac.uk/ontology-lookup/) or at BioPortal (http://bioportal.bioontology.org/). 
Integration of the HUPO Biology/Disease Human Proteome (B/D HPP) and C-HPP initiatives will be 
beneficial for both consortia because C-HPP can provide new assays for missing proteins or protein 
isoforms whose role and function can be immediately studied by B/D HPP teams in the context of 
health and disease. G-protein–coupled receptors, and especially olfactory receptors, are 
overrepresented among the missing proteins. This protein family is low abundant and shows highly 
specific tissue expression, and expression of the approximately 900 human olfactory receptors that are 
responsible for the detection of odorant compounds is only expected in nasal tissue. An assessment of 
the number of identified olfactory receptors in Kim et al.
72
 and Wilhelm et al.
131
 by Ezkurdia et al.
132
 
showed that these two large-scale studies with poor MS/MS spectra identified more than 100 olfactory 
receptors, despite the fact that they did not include data from nasal tissue. This quality assessment 
shows the importance of critical error analysis of peptide and protein identification in large-scale data 
analysis projects. The use of a 1% threshold for FDR limited only to PSM or peptide levels is not 
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sufficient to provide a high-quality list of identified proteins in large aggregated datasets. Therefore the 
statistical criteria must be a 1% FDR or better calculated at the protein level for the combined dataset as 
adopted by PeptideAtlas
11, 17
. Using a 1% FDR threshold at the PSM or peptide level would result in a 
large number of misidentified or indistinguishable proteins when analyzing a large amounts of data. 
These incorrect PSMs map to proteins randomly, which results in a greater FDR at the protein level. 
Setting an FDR should take into account the number of identified peptides and proteins in large 
datasets. For example, if a million PSM pass a threshold of 1% FDR, this implies that there are 10,000 
false PSMs, and these tend to map to proteins with one peptide per protein, which results in large FDR 
at the protein level. For datasets from which 3000 proteins are identified, a 1% protein-level FDR 
implies only 30 incorrect protein identifications. However, for very large datasets from which 15,000 
proteins are identified, a 1% protein-level FDR would result in 150 misidentified proteins, which is a 
considerable number. In this case, lowering the FDR to 0.1% for example, would keep the number of 
misidentified proteins at more acceptable number of approximately 15. C-HPP will stringently identify 
olfactory receptors in nasal tissue accompanied with thorough FDR analysis at the PSM, peptide and 
protein levels. 
 
Bioinformatics resources 
High-level bioinformatics support is crucial for the success of the C-HPP initiative and goes beyond the 
already-listed sequence knowledge bases, MS databases and SRM assay development support, and 
evaluation pipelines. Many groups have developed Human Proteome Browsers to support the 
chromosome-centric integration, processing, and visualization of proteogenomic data or MS/MS 
repositories such as the Gene-Centric Knowledgebase
133, 134
, GenomeWideDB
135
 [poster 4], Human 
Proteome Map
72
, proteomicsDB
131
, gpmDB
18
, PeptideAtlas
11, 12, 91
, HPA
6, 30, 31, 109
, The Proteome 
Browser
136
, CAPER
137, 138
 [poster 2], and Human Proteinpedia
139-141
. These resources are currently 
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being developed in isolation, which makes it difficult to further interrogate the diverse types of 
information stored in these resources. With the participation of the major database developers listed 
previously (Figure 1), an initiative to create at Unified Human Proteome Browser [poster 16] as an 
advanced knowledge-mining system was established at HUPO 2014 in Madrid. This builds on the 
strengths of existing browsers and their development teams to provide a unified platform for further 
detailed analysis of the acquired proteogenomic data from the perspectives of chromosomes, biology, 
and disease. This will lead to a better overview of the existing proteogenomic information that can be 
developed to suit the needs of the global proteomics community and to improve the current standards 
of data processing, visualization, and interpretation. It will be essential to subject the component 
resources and their overall performance to comparisons of assumptions, methods, or findings. 
The importance of the quality of bioinformatics workflows and use of false-discovery thresholds was 
demonstrated by Eric Deutsch, who showed that the addition of four large datasets (the CPTAC 
repository
142
 and those of Kim et al.
72
, Wilhelm et al.
131
, and Guo et al.
143
) to PeptideAtlas
11, 12, 91
 only 
increased the amount of level 1 protein evidence for approximately 1365 neXtProt entries using 
stringent error thresholds of 0.000091 FDR for PSMs, 0.00028 FDR at peptide level, and 0.011 FDR at 
protein level identification. The successive increments in HumanAll build database of PeptideAtlas 
from these new large studies were 541, 591, 231, and 2 proteins. gpmDB, PeptideAtlas, and neXtProt 
each estimated the high-quality protein identifications from Kim et al.
39
 and Wilhelm et al.
60
 to be 
about 13,000, not 17,294 or 18,059, as reported. Further scientific scrutiny of the many reasons for 
these large discrepancies will be desirable, involving all parties, as launched in Madrid. 
The proteomics community has a great deal of experience with over-calling protein identifications 
when stringent FDR thresholds are not maintained. The sensitivity to protein matching protocols can be 
illustrated with the results from the HUPO Human Plasma Proteome Project (HPPP). The original 
HPPP team paper
144
 highlighted a “core dataset” of 3020 proteins with two or more peptide matches, 
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but clearly delineated a broad range of values with other criteria. In contrast, States et al.
145
 published a 
uniquely stringent version of the same heterogeneous data utilizing Bonferroni-type adjustment for 
multiple comparisons with 889 protein identifications. In 2011, Farrah et al.
41
 published a Cedar 
scheme (Figure S1 in the supporting information) for HPPP that demonstrated stepwise recognition of 
1929 canonical proteins (1% protein-level FDR) + 236 possibly distinguished, totaling 2165 not 
subsumed; + 2507 subsumed = 4672 peptide-set unique; + 5686 indistinguishable = 9358 sequence-
unique; + 10,102 identical = 19,460 exhaustive list (suitable for cross-checking a different canonical set 
to see whether the match was lost in the choice of a “representative protein”; see Figure S1 in the 
supporting information). By 2014 the Human Plasma Proteome had grown to 4005 canonical proteins, 
as documented in the comparison of kidney, urine, and plasma proteomes
10
. 
The Spanish chromosome 16 team developed a method using transcription data from public 
repositories (GEO
146, 147
) obtained with cancer samples, cell lines, and healthy tissues to identify 
samples that showed enrichment for missing proteins [poster 12]. The data analysis showed that 2861 
missing protein-coding genes were expressed at the mRNA level in at least one sample, and that the 
majority of the genes showed sample specificity. Their study confirmed that the missing proteins are 
typically shorter and of lower abundance than those that have been identified. Transmembrane, 
cytoskeleton, signal transduction, spermatogenesis, zinc finger domains, synapses, neurotransmitter 
activity, and olfactory transduction are enriched cellular functions among the missing proteins
148
. All of 
these data will be available in the dasHPPboard webtool (http://sphppdashboard.cnb.csic.es/) [poster 
10], which has the goal of creating a similar initiative for storing and accessing the processed data 
generated by the C-HPP projects in a manner similar to that of ENCODE
46, 47
. 
To support the C-HPP initiative, Islam et al.
149
 developed the Protannotator tool to provide extensive 
annotation of missing proteins. Protannotator consists of a generic pipeline incorporating 
bioinformatics and annotation tools to identify homologues and to map putative functional signatures, 
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gene ontology, and biochemical pathways. Sequential BLAST searches originally developed for 
chromosome 7
150
 can be used to identify homologues from nonhuman mammalian proteins with strong 
protein evidence or homologues with validated human proteins. The Protannotator tool identified 
nonhuman mammalian homologues with protein evidence for 1271 missing proteins in other 
mammalian species, and 564 missing protein sequences were homologues to the reviewed human 
proteins. Functional annotations for the remaining missing proteins support the identification of 
possible biological sources and conditions under which the remaining missing proteins may be 
expressed. The tool also generates in silico proteotypic peptides, which facilitate the development of 
SRM assays. A search of these proteotypic peptides in ENCODE
46, 47
 revealed proteomic evidence for 
107 missing proteins, with evidence for an additional 15 missing proteins using the data of a recent 
membrane proteomic study
149
. 
NeXtProt provides primarily web-based protein evidence information, but also enables retrieval of data 
in various output formats (HTML, JavaScript Object Notation [JSON] and XML) using the REST 
Application Programming Interface (www.nextprot.org/rest/). In addition, neXtProt provides 
“chromosome reports” on its ftp server to support C-HPP projects. At the workshop in Segovia, the 
neXtProt team announced the development of an advanced search engine based on SPARQL that will 
enable complex and powerful queries, including federated queries with external resources
151
. 
Conclusions 
The reduction of the proportion of missing proteins in the human proteome from 33% to 18% (or 15%) 
over the last four years shows the clear progress of the C-HPP, which is mainly due to the application 
of improved proteomics technology such as specific sample preparation (e.g., antibody-based 
enrichment and enrichment of hydrophobic peptides), the use of advanced spectrometers, the 
application of SRM and SWATH assays for missing proteins [poster 3 and 14], and the analysis of 
unusual human sample types [posters 6, 7, 11, 13, and 15]. As the results approach saturation of the 
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parts list for protein-coding genes, it will be ever more important to apply stringent FDR criteria to the 
claims of protein matches and to confirm the findings with orthogonal methods. “One-hit wonders,” 
especially of short peptides, and claims of matches in tissue or cell types without transcript expression 
or that have not previously shown evidence of such proteins with modern instruments should be viewed 
with skepticism. The quality of the spectra must be examined, keeping in mind that when Ezkurdia et 
al.
132
 examined the spectra for hundreds of olfactory receptor proteins claimed by Kim et al.
72
 and by 
Wilhelm et al.
131
, none survived scrutiny. Likewise, peptides with multiple matches may be more likely 
to represent known, highly expressed proteins with a single mutation or an RNA-edited site than a 
“missing protein.” The C-HPP has also encouraged analyses of amplicons (cis-regulated genes in 
specific chromosomal segments) and of protein families, as well as the recognition of proteins that are 
unlikely to be detected for the reasons outlined in Figure 2. 
Proteogenomic analysis integrating data from genomics, transcriptomics, and proteomics is gaining 
momentum and results in an addition to the human proteome protein forms that arise from genetic 
variability, such as SAVs, RNA-editing, and alternative splicing. Proteogenomic technology now 
allows the routine study of these new protein forms in biological processes to unravel their roles in 
various diseases. Spectral libraries of synthetic peptides for almost all human proteins, together with 
the large number of antibodies generated by the HPA, permits the functional analysis of proteins and 
protein forms in biological experiments with complex designs. Bioinformatics support for the C-HPP 
has been largely developed during the last four years and has contributed to its success not only by 
reducing the number of missing proteins, but also in aiding the discovery of multiple new protein 
forms. 
It is clear that work must still be undertaken to confirm the presence of the remaining missing proteins, 
which will become more and more challenging as the completion of the MS-based evidence of the 
human proteome on the gene basis is reached. C-HPP members are increasing their activities to find 
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evidence for the remaining missing human proteins and to discover more and more complete sets of 
protein forms that reflect genetic variability and post-translational modifications. 
The C-HPP posters presented at HUPO 2014 in Madrid (Table 1) are available online at the Journal of 
Proteome Research as supporting information, including the poster’s abstract, and most of the oral 
presentations can be found at C-HPP Wiki (http://c-hpp.webhosting.rug.nl/). 
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Figure 1. Bioinformatics resources to support the discovery, cataloging and browsing of protein part lists. Raw MS data acquired in different 
laboratories are deposited in the storage resources from the ProteomeXchange consortium. At present MS/MS datasets are fully supported by 
PRIDE and MassIVE, whereas SRM datasets are supported by PASSEL. Once is made publicly available, data in ProteomeXchange can be 
further used by many resources, for example reprocessing by PeptideAtlas using the Trans Proteomic Pipeline, or e.g. used by other Protein 
Browser resources. SRMAtlas, SRMQuanAtlas, SWATHAtlas with PeptideAtlas and other spectral libraries form the rich resources to 
develop or implement SRM assays. NeXtProt integrates data on proteins using 14 different resources and classifies proteins in 5 existence 
categories. C-HPP at HUPO 2014 in Madrid launched the Unified Human Proteome Browser Initiative to provide a unified view of the 
acquired proteogenomic data from a chromosome, biology and disease perspective. 
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Figure 2. The five main reasons for proteins without evidence at the protein level (missing proteins) are: (1) current proteomics technology 
is not able to detect them due to uncovered chemical space of the applied mainstream analytical method, (2) expression heterogeneity of 
protein present only in rare and not yet analyzed samples, (3) silent genes present only in the genome, but never expressed, and (4) error in 
genome annotation, or (5) proteins missed or not counted due to parsimonious protein identification of shotgun proteomics database search 
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approach leading to simplification of protein representation of highly homologous proteins of the same protein family in databases such as 
PeptideAtlas, neXtProt, and gpmDB
40
 or to large sequence variability such as immunoglobulins. Proteomics technology (1) can be improved 
with techniques such as subcellular fractionation or specific enrichment of membrane proteins, while low abundant proteins can be detected 
either with enrichment using monoclonal and polyclonal antibodies or/and using sensitive SRM and SWATH analysis. Expression 
heterogeneity (4) can be improved by joining forces with biology/disease driven research groups for example by enhancing collaboration 
between C-HPP and B/D HPP teams. Proteogenomic approach integrating genome, transcriptome with proteome data helps in general to (5) 
identify protein forms originating from genetic variability and (3) may correct for genome annotation errors. Use of multiple protease 
enhance protein coverage and can lead to distinction of highly homologous proteins (5) in main protein evidence databases. The most 
challenging group of missing proteins are silent genes (2) which are not normally expressed during the life cycle of an individual but can be 
activated by mutation, recombination, insertion elements, or other genetic mechanisms.  
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Figure 3. The number of chromosome 19 genes
152
 and the identified molecular entities at transcript and expression levels (mRNA and 
proteins) are illustrated as a proteogenomic analysis of Glioma stem cells addressed the challenges integrating genomics, transcriptomics and 
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proteomics data. Although, the figure presents the current status of chromosome 19, the number of “missing” consensus proteins and their 
alternative forms, including ASV, new ORFs and new SAVs, is proportionally similar of other human chromosomes. 
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Poster 
number 
Title Chr team Main topic 
1 Mining Missing Membrane Proteins from Lung Cancer Tissues and Cell lines 4 Proteomics technology: 
opening chemical space 
2 CAPER 3.0: a scalable cloud-based pipeline for the data-intensive analysis of proteomic datasets 1, 8, 20 Bioinformatics: proteome 
browser 
3 Chromosome 18: Master Proteome 18 Proteomics technology: 
lowering detection limit 
4 GenomewidePDB v 2.0: Update on the transcriptomic and proteomic expression data with 
alternatively spliced products layered in a genome-wide manner 
13 Bioinformatics: proteome 
browser 
5 Development of improved subcellular fractionation procedures of the placental membrane 
proteins for discovering disease biomarkers and missing proteins 
13 Proteomics technology: 
lower detection limit 
6 Chromosome X X Missing protein: 
identification strategy 
7 The Mitochondrial Human Proteome Project - MT-HPP Mitochondria Missing protein: 
identification strategy 
8 Revisiting the Identification of Canonical Splice lsoforms through Integration of Functional 
Genomics and Proteomics Evidence from the Chromosome 17 Human Proteome Project 
17 Exploring effect of genetic 
variability 
9 Subcellular fractionation enhances Chromosome 16 Proteome Coverage 16 Proteomics technology: 
lowering detection limit 
10 Proteogenomics Dashboard for the Human Proteome Project 16 Bioinformatics: 
proteogenomic data 
mining 
11 Missing proteins in Chromosome 16 Spanish HPP 16 Missing protein: 
identification strategy 
12 Transcriptomic profiling towards the localization of the missing proteins 16 Missing proteins: 
identification with 
proteogenomic 
13 The Chromosome 19 Strategy to Characterize Novel Proteoforms and Missing Proteins Using 
ENCODE Resources 
19 Missing protein: 
identification with 
proteogenomic 
14 Targeting proteins of chromosome 16 16 Proteomics technology: 
lower detection limit 
15 Dissecting Chromosome 16 proteome 16 Missing protein: 
identification strategy 
16 Unified Human Proteome Browser Initiative all Bioinformatics: proteome 
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browser 
17 Expression of αvβ6 integrin enhances both plasminogen and latent-transforming growth factor-
β1 dependent proliferation, invasion and ERK1/2 signaling in colorectal cancer cells 
7 Proteomics technology: 
application 
18 Overexpression of αvβ6 integrin alters the colorectal cancer cell proteome in favor of elevated 
proliferation and a switching in cellular adhesion which increases invasion 
7 Proteomics technology: 
application 
19 Approaching the organellar brain proteome to understand the molecular basis of Schizophrenia 15 Protein quantification: 
application. Missing 
proteins. 
20 Splice Variants in Aggressive Human Triple Negative Breast Cancer 17 Exploring effect of genetic 
variability 
21 Revisiting the Identification of Canonical Splice Isoforms through Integration of Functional 
Genomics and Proteomics Evidence from the Chromosome 17 Human Proteome Project 
17 Exploring effect of genetic 
variability 
 
Table 1. List of posters presented at C-HPP poster session on 7 October 2014 at HUPO 2014 (Madrid), and used as second reference (poster 
number) in this paper. 
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